Maravai LifeSciences Holdings Stock
Maravai LifeSciences Holdings, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Bernd Brust
- Employees
- 415
- Market cap
- $1.9 B
- IPO
- 20/11/2020
Maravai LifeSciences Holdings, Inc. is a healthcare company operating globally with its headquarters located in San Diego, US. Founded in 2020, the company provides essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. The company…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Maravai LifeSciences Holdings stock: price history
1D
-4.0%
1W
-8.7%
1M
-0.7%
6M
+100.3%
YTD
+108.9%
1Y
+94.6%
2Y
-17.9%
5Y
-81.7%
10Y
–
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~111% stronger price swings than usual
Maravai LifeSciences Holdings stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 01/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
3 more assignments (Enabler/Second row) Pro-only.
Maravai LifeSciences Holdings, Inc. is a globally operating biosciences company that supplies essential products for the development of therapeutics, vaccines, and diagnostics. The business model comprises two operating segments: Nucleic Acid Production provides components such as mRNA, plasmids, and proprietary CleanCap technologies for gene therapy and diagnostics. The Biologics Safety Testing segment offers analytical solutions such as ELISA kits and customized services for identifying contaminants in bioprocesses. The customer base consists of biopharmaceutical companies, research institutions, and diagnostics manufacturers, positioning the company as a central player in the biotechnology value chain.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- None
- Moat type
- None
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Maravai LifeSciences Holdings
Analyst assessment of Maravai LifeSciences Holdings
PRICE TARGET LOW
US$6.00
CONSENSUS
US$7.00
MEDIAN
US$7.00
PRICE TARGET HIGH
US$8.00
0
STRONG BUY
7
BUY
6
HOLD
1
SELL
0
STRONG SELL
14
TOTAL · Buy
As of: 09/09/2026
Maravai LifeSciences Holdings stock metrics
P/E
-12.68
P/B
4.91
EV/EBITDA
-36.57
RETURN ON EQUITY
-6.1%
NET MARGIN
-24.1%
DEBT/EQUITY
0.86
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
71.4%
FLOAT SHARES
106,403,863
AVG. DAILY VOLUME (30D)
2,641,039
Insider transactions (SEC)
Brust Bernd
Asarpota Rajesh
Brust Bernd
Asarpota Rajesh
Brust Bernd
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -4.0%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Maravai LifeSciences Holdings stock
What does Maravai LifeSciences Holdings do?
Maravai LifeSciences Holdings, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Bernd Brust, the company employs around 415 people.
The IPO was on 20/11/2020; the stock trades on NASDAQ under the ticker MRVI.
What do analysts say about Maravai LifeSciences Holdings stock?
14 analysts rate the stock, the consensus is Buy (as of 09/09/2026).
The average price target is US$7.00, ranging from US$6.00 to US$8.00, with a median of US$7.00.
This is an external assessment, not a statement by Market Jury.
When does Maravai LifeSciences Holdings report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 111% stronger than usual.
Does Maravai LifeSciences Holdings pay a dividend?
No, Maravai LifeSciences Holdings currently does not pay a dividend.
Which stocks are comparable to Maravai LifeSciences Holdings?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Maravai LifeSciences Holdings stock analyzed?
Clicking "Analyze stock" lets five strategies assess Maravai LifeSciences Holdings against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.